As we move into 2023, BioSpace takes a pause to reflect on the year gone by and some of the most remarkable news bits, looking at the top five noteworthy FDA drug and biologic therapy approvals in 2022.
Tag Archive for: Camzyos
The agency’s top five represent an eclectic mix of cancer, cardiovascular and rare disease drugs.
